分子感染症検査市場規模、シェア、動向、2031年までの世界予測

分子感染症検査市場は、2026年の113億米ドルから2031年には190億9000万米ドルに成長し、成長率は11.1%に達するとMarketsandMarketsでは予測しています。

この市場の成長を牽引する主要因は、分子診断技術の急速な進歩です。PCRや次世代シーケンシングなどの技術革新により、検査の精度、速度、効率性が向上し、より手頃な価格で広く利用できるようになりました。

さらに、市場の企業は高度な自動診断システムを継続的に開発しています。これにより、感染症のより正確かつ迅速な検出が可能になり、患者の予後改善や新興病原体の監視強化につながります。結果として、医療従事者は感染症に対する分子診断の適用に関して、より的確な判断を下せるようになります。

調査範囲：

本調査レポートは、分子感染症検査市場を、製品・サービス（試薬・キット、機器、サービス・ソフトウェア）、タイプ（シングルプレックス検査、マルチプレックス検査）、検査タイプ（臨床検査、ポイントオブケア検査）、疾患［呼吸器感染症（インフルエンザ、結核、咽頭炎、その他の呼吸器感染症）、消化器感染症（肝炎、その他の消化器感染症）、性感染症（ヒト免疫不全ウイルス、クラミジア・トラコマチス、淋菌、梅毒、ヒトパピローマウイルス、その他の性感染症）、膣炎、髄膜炎、媒介性疾患、院内感染、その他の感染症］、技術（ポリメラーゼ連鎖反応、in situハイブリダイゼーション、等温核酸増幅法、DNAシーケンシング・次世代シーケンシング、DNAマイクロアレイ、その他）別に分類しています。

本レポートは、分子感染症検査市場の成長に影響を与える主要な要因（推進要因、阻害要因、機会、課題など）に関する詳細な情報を提供します。主要企業については、事業概要、ソリューション、主要戦略、買収、契約に関する詳細な分析を実施しました。また、分子感染症検査市場における新製品・新サービスの発表や最近の動向についても取り上げています。さらに、分子感染症検査市場のエコシステムにおける新興企業の競合分析も行っています。

本レポートを購入する理由：

本レポートは、市場リーダー企業と新規参入企業に対し、分子感染症検査市場全体およびそのサブセグメントの収益に関する貴重な洞察を提供します。関係者は競争環境を理解し、自社の事業をより効果的に位置づけ、効果的な市場参入戦略を策定することができます。さらに、本レポートは、主要な推進要因、阻害要因、機会、課題を明らかにし、現在の市場動向に関する洞察を提供します。

本レポートは、以下のポイントに関する洞察を提供します。

分子感染症検査市場の成長に影響を与える主要な推進要因（世界的な感染症負担の増大、分子診断技術の進歩、分子検査への資金提供の増加、早期発見への意識の高まり）、阻害要因（標準化された償還制度の欠如、機器および消耗品の高コスト）、機会（新興国における拡大の可能性、ポイントオブケア（POC）検査への需要の高まり）、および課題（厳格かつ多様な規制要件、運用上の障壁と労働力不足、試薬およびキットのサプライチェーンの混乱）の分析。

• 製品開発／イノベーション：分子感染症検査市場における今後の技術、研究開発活動、および新製品の発売に関する詳細な洞察。
• 市場開発：有望な市場に関する包括的な情報。本レポートは、様々な地域における分子感染症検査市場を分析します。
• 市場の多様化：分子感染症検査市場における新製品、未開拓地域、最近の動向、および投資に関する包括的な情報。
• 競合分析：ダナハー（米国）、F・ホフマン・ラ・ロシュ（スイス）、バイオメリュー（フランス）、ホロジック（米国）、アボット（米国）といった主要企業の市場シェア、成長戦略、製品ラインナップを詳細に分析します。

Report Description

The market for molecular infectious disease testing is expected to grow from USD 11.30 billion in 2026 to reach USD 19.09 billion by 2031, at a growth rate of 11.1%. The rapid advancement of molecular diagnostic techniques is a key driver of this market’s growth. Innovations such as PCR and next-generation sequencing enhance the accuracy, speed, and efficiency of tests, making them more affordable and widely accessible.

Furthermore, companies in the market are continuously developing advanced automated diagnostic systems. This leads to more precise and rapid detection of infectious diseases, resulting in improved patient outcomes and better monitoring of emerging pathogens. Consequently, healthcare providers can make more informed decisions regarding the application of molecular diagnostics for infectious diseases.

“The laboratory tests segment is expected to witness the fastest growth rate in the molecular infectious disease testing market, by test type, during the forecast period.”

The market for molecular infectious disease testing can be divided into two main categories: laboratory tests and point-of-care tests, depending on the type of test. The laboratory tests segment is the fastest-growing due to its high accuracy and efficiency, as these tests can detect a wide range of pathogens. Laboratory tests, including PCR testing and sequencing-based testing, are particularly popular among hospitals and diagnostic laboratories because they provide precise disease identification. Significant advances in lab automation and high-throughput systems have enabled these tests to be performed efficiently. Additionally, there is a growing demand for comprehensive diagnostic tests that can detect multiple infections in a single test, further enhancing the preference for laboratory testing. With their reliable results and high diagnostic capabilities, laboratory tests offer an effective solution for detecting infectious diseases.

“The multiplex testing segment accounted for the largest market share, by type, in 2025.”

The global market for molecular infectious disease testing can be divided into two main segments: singleplex testing and multiplex testing. Among these, multiplex testing leads the market due to its ability to run multiple tests simultaneously, enabling the detection and differentiation of various pathogens in a single test. This capability not only saves time, money, and effort but also makes it the preferred choice for healthcare providers. Additionally, the rise in co-infections, the need for comprehensive diagnostic tests, and the demand for accurate results in shorter timeframes have all contributed to the growth of the multiplex testing market.

“The Asia Pacific is the fastest-growing market for molecular infectious disease testing during the forecast period.”

The global market for molecular infectious disease testing is segmented into the following regions: North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and the GCC countries. The market is experiencing significant growth, particularly in the Asia Pacific region, driven by the high prevalence of infectious diseases in densely populated areas. There is a growing emphasis on early disease detection, which increases the demand for advanced diagnostic tools. Government and healthcare organizations are making substantial investments to enhance healthcare infrastructure, improve diagnostic facilities, and support research initiatives. Additionally, a focus on disease surveillance, outbreak management, and increased healthcare expenditure further contributes to the Asia Pacific region’s significant role in the overall growth of the molecular infectious disease testing market.

The breakdown of the profile of primary participants in the molecular infectious disease testing market is:

• By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%)
• By Designation: C-level Executives (27%), Directors (18%), and Other Designations (55%)
• By Region: North America (51%), Europe (21%), Asia Pacific (18%), Latin America (6%), and the Middle East & Africa (4%)

The key players in the molecular infectious disease testing market are Danaher (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), QuidelOrtho Corporation (US), DiaSorin S.p.A. (Italy), Bruker (US), Seegene Inc. (South Korea), Genetic Signatures (Australia), Co-Diagnostics, Inc. (US), Savyon Diagnostics (Israel), Vela Diagnostics (Singapore), Molbio Diagnostics Pvt. Ltd. (India), Uniogen OY (Finland), geneOmbio Technologies (India), Advanced Molecular Diagnostics (UK), GeneFirst Limited (UK), and altona Diagnostics GmbH (Germany).

Research Coverage:

This research report categorizes the molecular infectious disease testing market by product & service (reagents & kits, instruments, and services & software), by type (singleplex testing and multiplex testing), by test type (laboratory tests and point-of-care tests), by disease [respiratory infectious diseases (influenza, tuberculosis, pharyngitis, and other respiratory infectious diseases), gastrointestinal infectious diseases (hepatitis and other gastrointestinal infectious diseases), sexually transmitted diseases (human immunodeficiency virus, chlamydia trachomatis, neisseria gonorrhoea, syphilis, human papillomavirus, and other sexually transmitted diseases), vaginitis, meningitis, vector-borne diseases, hospital-acquired infections, and other infectious diseases], by technology (polymerase chain reaction, in situ hybridization, isothermal nucleic acid amplification technology, DNA sequencing & next-generation sequencing, DNA microarrays, and other technologies), by end user (diagnostic laboratories, hospitals & clinics, and other end users), and region (North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and the GCC countries).

The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges, influencing the growth of the molecular infectious disease testing market. A detailed analysis of key industry players has been conducted to provide insights into their business overviews, solutions, key strategies, acquisitions, and agreements. New product & service launches, and recent developments associated with the molecular infectious disease testing market. This report covers the competitive analysis of upcoming startups in the molecular infectious disease testing market ecosystem.

Reasons to buy this report:

The report will provide market leaders and newcomers with valuable insights into the revenue figures for the overall molecular infectious disease testing market and its subsegments. It will help stakeholders comprehend the competitive landscape, enabling them to better position their businesses and formulate effective go-to-market strategies. Additionally, the report will offer insights into the current market dynamics, highlighting key drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (growing global infectious disease burden, advancements in molecular diagnostic technologies, growing funding for molecular testing, and growing awareness of early disease detection), restraints (lack of standardized reimbursement structures and high cost of instruments and consumables), opportunities (expansion potential across emerging economies, rising demand for point-of-care (POC) testing), and challenges (stringent and varying regulatory requirements, operational barriers and labor shortage challenges, and supply chain disruptions for reagents and kits) influencing the growth of the molecular infectious disease testing market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the molecular infectious disease testing market.
• Market Development: Comprehensive information about lucrative markets; the report analyzes the molecular infectious disease testing market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the molecular infectious disease testing market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like Danaher (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux (France), Hologic, Inc. (US), and Abbott (US).

Table of Contents

1 INTRODUCTION 40
1.1 STUDY OBJECTIVES 40
1.2 MARKET DEFINITION 40
1.3 STUDY SCOPE 41
1.3.1 MARKETS COVERED & REGIONAL SCOPE 41
1.3.2 INCLUSIONS & EXCLUSIONS 42
1.3.3 YEARS CONSIDERED 42
1.4 CURRENCY CONSIDERED 43
1.5 STAKEHOLDERS 43
1.6 SUMMARY OF CHANGES 43
2 EXECUTIVE SUMMARY 45
2.1 KEY INSIGHTS & MARKET HIGHLIGHTS 45
2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS 46
2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH 47
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 48
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 49
3 PREMIUM INSIGHTS 50
3.1 MOLECULAR INFECTIOUS DISEASE TESTING MARKET OVERVIEW 50
3.2 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2026 VS. 2031 50
3.3 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2026 VS. 2031 51
3.4 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2026 VS. 2031 51
3.5 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2026 VS. 2031 52
3.6 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2026 VS. 2031 52
3.7 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2026 VS. 2031 53
3.8 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 53
4 MARKET OVERVIEW 54
4.1 INTRODUCTION 54
4.2 MARKET DYNAMICS 54
4.2.1 DRIVERS 55
4.2.1.1 Growing global infectious disease burden 55
4.2.1.2 Advancements in molecular diagnostic technologies 57
4.2.1.3 Growing funding for molecular testing 57
4.2.1.4 Growing awareness of early disease detection 58
4.2.2 RESTRAINTS 58
4.2.2.1 Lack of standardized reimbursement structures 58
4.2.2.2 High cost of instruments and consumables 59
4.2.3 OPPORTUNITIES 59
4.2.3.1 Expansion potential across emerging economies 59
4.2.3.2 Rising demand for point-of-care (POC) testing 60
4.2.4 CHALLENGES 61
4.2.4.1 Stringent and varying regulatory requirements 61
4.2.4.2 Operational barriers and labor shortage challenges 61
4.2.4.3 Supply chain disruptions for reagents and kits 62
4.3 UNMET NEEDS & WHITE SPACES 63
4.3.1 UNMET NEEDS IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET 63
4.3.2 WHITE SPACE OPPORTUNITIES 63
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 64
4.4.1 INTERCONNECTED MARKETS 64
4.4.2 CROSS-SECTOR OPPORTUNITIES 65
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 66
4.5.1 KEY MOVES & STRATEGIC FOCUS 66
5 INDUSTRY TRENDS 67
5.1 PORTER’S FIVE FORCES ANALYSIS 67
5.1.1 BARGAINING POWER OF SUPPLIERS 68
5.1.2 BARGAINING POWER OF BUYERS 68
5.1.3 THREAT OF NEW ENTRANTS 68
5.1.4 THREAT OF SUBSTITUTES 68
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 69
5.2 MACROECONOMIC INDICATORS 69
5.2.1 INTRODUCTION 69
5.2.2 GDP TRENDS & FORECAST 69
5.3 SUPPLY CHAIN ANALYSIS 72
5.4 VALUE CHAIN ANALYSIS 73
5.5 ECOSYSTEM ANALYSIS 75
5.5.1 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: ROLE OF COMPANIES IN ECOSYSTEM 75
5.6 PRICING ANALYSIS 76
5.6.1 AVERAGE SELLING PRICE TREND OF MOLECULAR INFECTIOUS DISEASE TESTING PRODUCTS, BY KEY PLAYER, 2024–2026 76
5.6.2 AVERAGE SELLING PRICE TREND OF MOLECULAR INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2024–2026 77
5.7 TRADE ANALYSIS 78
5.7.1 IMPORT SCENARIO (HS CODE 3822) 78
5.7.2 EXPORT SCENARIO (HS CODE 3822) 79
5.8 KEY CONFERENCES & EVENTS, 2026–2027 80
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 81
5.10 INVESTMENT & FUNDING SCENARIO 81
5.11 IMPACT OF 2025 US TARIFFS ON MOLECULAR INFECTIOUS DISEASE TESTING MARKET 82
5.11.1 INTRODUCTION 82
5.11.2 KEY TARIFF RATES 82
5.11.3 PRICE IMPACT ANALYSIS 83
5.11.4 IMPACT ON REGIONS 83
5.11.4.1 North America 84
5.11.4.2 Europe 84
5.11.4.3 Asia Pacific 84
5.11.5 IMPACT ON END-USE INDUSTRIES 85
5.11.5.1 Diagnostic laboratories 85
5.11.5.2 Hospitals & clinics 85
5.11.5.3 Other end users 85
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 86
6.1 KEY EMERGING TECHNOLOGIES 86
6.1.1 NEXT-GENERATION SEQUENCING 86
6.1.2 POLYMERASE CHAIN REACTION 86
6.2 COMPLEMENTARY TECHNOLOGIES 87
6.2.1 BIOINFORMATICS & DATA ANALYTICS PLATFORMS 87
6.2.2 LABORATORY INFORMATION SYSTEMS (LIS) & DIGITAL HEALTH INTEGRATION 87
6.3 ADJACENT TECHNOLOGIES 88
6.3.1 CRISPR-BASED DIAGNOSTICS 88
6.3.2 DIGITAL PCR (DPCR) 88
6.4 TECHNOLOGY/PRODUCT ROADMAP 89
6.5 PATENT ANALYSIS 90
6.5.1 LIST OF MAJOR PATENTS 91
6.6 FUTURE APPLICATIONS 92
6.7 IMPACT OF AI/GENERATIVE AI ON MOLECULAR INFECTIOUS DISEASE TESTING MARKET 93
6.7.1 INTRODUCTION 93
6.7.2 TOP USE CASES & MARKET POTENTIAL 94
6.7.3 KEY COMPANIES IMPLEMENTING AI 94
6.7.4 FUTURE OF AI 95
7 SUSTAINABILITY & REGULATORY LANDSCAPE 96
7.1 REGIONAL REGULATIONS & COMPLIANCE 96
7.1.1 REGULATORY ANALYSIS 96
7.1.1.1 North America 96
7.1.1.1.1 US 96
7.1.1.1.2 Canada 96
7.1.1.2 Europe 96
7.1.1.2.1 Germany 97
7.1.1.2.2 UK 98
7.1.1.2.3 France 98
7.1.1.2.4 Italy 98
7.1.1.3 Asia Pacific 99
7.1.1.3.1 China 99
7.1.1.3.2 Japan 99
7.1.1.3.3 India 99
7.1.1.3.4 Australia 100
7.1.1.4 Latin America 100
7.1.1.4.1 Brazil 101
7.1.1.4.2 Mexico 101
7.1.1.5 Middle East 101
7.1.1.5.1 Africa 101
7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 102
7.2 SUSTAINABILITY INITIATIVES 103
7.2.1 ENVIRONMENTAL IMPACT & ECO-FRIENDLY INITIATIVES 103
7.2.1.1 Eco-friendly initiatives 104
7.2.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 105
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 106
8.1 DECISION-MAKING PROCESS 106
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 106
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 106
8.2.2 BUYING CRITERIA 107
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 108
8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 109
8.5 MARKET PROFITABILITY 110
8.5.1 REVENUE POTENTIAL 110
8.5.2 COST DYNAMICS 110
8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 111
9 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE 112
9.1 INTRODUCTION 113
9.2 REAGENTS & KITS 113
9.2.1 ONGOING INNOVATIONS IN MOLECULAR DIAGNOSTICS TO SPUR GROWTH 113
9.3 INSTRUMENTS 117
9.3.1 TECHNOLOGICAL ADVANCEMENTS TO FOSTER GROWTH 117
9.4 SOFTWARE & SERVICES 121
9.4.1 INCREASING UPTAKE OF ADVANCED INSTRUMENTS TO FACILITATE GROWTH 121
10 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE 125
10.1 INTRODUCTION 126
10.2 MULTIPLEX TESTING 126
10.2.1 RISING DEMAND FOR FASTER DIAGNOSIS TO PROMOTE GROWTH 126
10.3 SINGLEPLEX TESTING 130
10.3.1 NEED FOR AFFORDABLE AND USER-FRIENDLY TESTING TO AUGMENT GROWTH 130
11 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE 133
11.1 INTRODUCTION 134
11.2 LABORATORY TESTS 134
11.2.1 INCREASING NEED FOR AUTOMATION TO FAVOR GROWTH 134
11.3 POINT-OF-CARE TESTS 138
11.3.1 GROWING AWARENESS ABOUT DISEASE SURVEILLANCE, SCREENING, AND OUTBREAK RESPONSE TO DRIVE MARKET 138
12 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE 143
12.1 INTRODUCTION 144
12.2 RESPIRATORY INFECTIOUS DISEASES 144
12.2.1 INFLUENZA 148
12.2.1.1 Growing focus on faster diagnosis and control to propel market 148
12.2.2 TUBERCULOSIS 151
12.2.2.1 Rise in undiagnosed and untreated cases to promote growth 151
12.2.3 PHARYNGITIS 154
12.2.3.1 Need to differentiate between bacterial and viral infections to fuel growth 154
12.2.4 NON-TUBERCULOUS MYCOBACTERIA (NTM) LUNG INFECTIONS 156
12.2.4.1 Increasing reliance on advanced molecular diagnostic technologies to fuel growth 156
12.2.5 OTHER RESPIRATORY INFECTIOUS DISEASES 159
12.3 GASTROINTESTINAL INFECTIOUS DISEASES 162
12.3.1 HEPATITIS 165
12.3.1.1 Rising global incidence of infections to expedite growth 165
12.3.2 OTHER GASTROINTESTINAL INFECTIOUS DISEASES 168
12.4 SEXUALLY TRANSMITTED DISEASES 171
12.4.1 HUMAN IMMUNODEFICIENCY VIRUS 174
12.4.1.1 Increasing number of blood transfusions and blood donations to augment growth 174
12.4.2 HUMAN PAPILLOMAVIRUS 177
12.4.2.1 Technological advancements for preventing human papillomavirus infections to drive market 177
12.4.3 CHLAMYDIA TRACHOMATIS 180
12.4.3.1 Increasing incidence of chlamydia to aid growth 180
12.4.4 NEISSERIA GONORRHOEAE 183
12.4.4.1 Increasing development of novel assays to boost market 183
12.4.5 SYPHILIS 186
12.4.5.1 Growing demand for affordable and rapid molecular diagnostic solutions to drive market 186
12.4.6 OTHER SEXUALLY TRANSMITTED DISEASES 189
12.5 HOSPITAL-ACQUIRED INFECTIONS 192
12.5.1 GROWING BURDEN OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS TO FUEL MARKET 192
12.6 VAGINITIS 195
12.6.1 INCREASING AWARENESS ABOUT WOMEN’S HEALTH TO BOLSTER GROWTH 195
12.7 MENINGITIS 198
12.7.1 RISING INCIDENCE OF INVASIVE MENINGOCOCCAL DISEASE TO ASSIST GROWTH 198
12.8 VECTOR-BORNE DISEASES 201
12.8.1 GROWING FOCUS ON DISEASE SURVEILLANCE TO PROPEL MARKET 201
12.9 BLOODSTREAM INFECTIONS & SEPSIS 205
12.9.1 HIGH BURDEN OF BLOODSTREAM INFECTIONS TO PROPEL MARKET 205
12.10 OTHER INFECTIOUS DISEASES 208
13 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY 211
13.1 INTRODUCTION 212
13.2 POLYMERASE CHAIN REACTION 212
13.2.1 NEED FOR HIGH PRECISION FOR DISEASE IDENTIFICATION TO SUPPORT GROWTH 212
13.3 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY 217
13.3.1 EMERGENCE OF NEW PATHOGENS TO STIMULATE GROWTH 217
13.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING 220
13.4.1 GROWING APPLICATIONS IN DIAGNOSING BACTERIAL, VIRAL, FUNGAL, AND PARASITIC INFECTIONS TO DRIVE MARKET 220
13.5 IN SITU HYBRIDIZATION 223
13.5.1 NEED FOR SAFER AND MORE PRACTICAL TESTING IN CLINICAL SETTINGS TO FUEL MARKET 223
13.6 DNA MICROARRAYS 226
13.6.1 NEED FOR AFFORDABLE AND SENSITIVE DETECTION TO ENCOURAGE GROWTH 226
13.7 OTHER TECHNOLOGIES 228
14 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER 231
14.1 INTRODUCTION 232
14.2 DIAGNOSTIC LABORATORIES 232
14.2.1 GROWING EMPHASIS ON QUALITY CONTROL AND STANDARDIZED TESTING PROTOCOLS TO BOOST MARKET 232
14.3 HOSPITALS & CLINICS 235
14.3.1 RISING PATIENT VOLUMES TO CONTRIBUTE TO GROWTH 235
14.4 OTHER END USERS 238
15 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY REGION 240
15.1 INTRODUCTION 241
15.2 NORTH AMERICA 241
15.2.1 US 248
15.2.1.1 Presence of advanced healthcare infrastructure to augment growth 248
15.2.2 CANADA 252
15.2.2.1 Favorable government initiatives to fuel market 252
15.3 EUROPE 257
15.3.1 GERMANY 262
15.3.1.1 Increasing healthcare expenditure to advance growth 262
15.3.2 UK 266
15.3.2.1 Growing number of diagnostic centers to fuel market 266
15.3.3 FRANCE 271
15.3.3.1 Increasing demand for early disease diagnosis to augment growth 271
15.3.4 ITALY 275
15.3.4.1 Growing adoption of advanced diagnostic technologies to fuel market 275
15.3.5 RUSSIA 280
15.3.5.1 Increasing access to quality healthcare to facilitate growth 280
15.3.6 SPAIN 284
15.3.6.1 Growing public health initiatives to boost market 284
15.3.7 REST OF EUROPE 289
15.4 ASIA PACIFIC 294
15.4.1 CHINA 300
15.4.1.1 Rising public access to modern healthcare to spur growth 300
15.4.2 JAPAN 304
15.4.2.1 Universal healthcare reimbursement policy to foster growth 304
15.4.3 INDIA 309
15.4.3.1 Increased private and public investments to bolster growth 309
15.4.4 AUSTRALIA 313
15.4.4.1 Growing investments for testing centers and treatment facilities to drive market 313
15.4.5 REST OF ASIA PACIFIC 318
15.5 LATIN AMERICA 322
15.5.1 BRAZIL 328
15.5.1.1 Growing focus on improving healthcare infrastructure to fuel market 328
15.5.2 MEXICO 332
15.5.2.1 Increasing accessibility and affordability of healthcare services to foster growth 332
15.5.3 REST OF LATIN AMERICA 337
15.6 MIDDLE EAST & AFRICA 341
15.6.1 BOOMING HEALTHCARE INVESTMENTS TO AID GROWTH 341
15.7 GCC COUNTRIES 346
15.7.1 GROWING PUBLIC HEALTHCARE FUNDING TO DRIVE MARKET 346
16 COMPETITIVE LANDSCAPE 351
16.1 INTRODUCTION 351
16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 351
16.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET 351
16.3 REVENUE ANALYSIS, 2023–2025 353
16.4 MARKET SHARE ANALYSIS, 2025 354
16.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025 354
16.4.2 US MARKET SHARE ANALYSIS, 2025 356
16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 356
16.5.1 STARS 356
16.5.2 EMERGING LEADERS 357
16.5.3 PERVASIVE PLAYERS 357
16.5.4 PARTICIPANTS 357
16.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 358
16.5.5.1 Company footprint 358
16.5.5.2 Region footprint 358
16.5.5.3 Product & service footprint 359
16.5.5.4 Disease footprint 360
16.5.5.5 Test type footprint 361
16.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 361
16.6.1 PROGRESSIVE COMPANIES 361
16.6.2 RESPONSIVE COMPANIES 361
16.6.3 DYNAMIC COMPANIES 362
16.6.4 STARTING BLOCKS 362
16.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 363
16.6.5.1 Detailed list of key startups/SMEs 363
16.6.5.2 Competitive benchmarking of startups/SMEs (1/2) 363
16.6.5.3 Competitive benchmarking of startups/SMEs (2/2) 364
16.7 COMPANY VALUATION & FINANCIAL METRICS 364
16.7.1 FINANCIAL METRICS 364
16.7.2 COMPANY VALUATION 365
16.8 BRAND/PRODUCT COMPARISON 365
16.9 COMPETITIVE SCENARIO 366
16.9.1 PRODUCT LAUNCHES & APPROVALS 366
16.9.2 DEALS 367
16.9.3 EXPANSIONS 368
17 COMPANY PROFILES 369
17.1 KEY PLAYERS 369
17.1.1 DANAHER 369
17.1.1.1 Business overview 369
17.1.1.2 Products offered 370
17.1.1.3 Recent developments 372
17.1.1.3.1 Product approvals 372
17.1.1.3.2 Deals 373
17.1.1.4 MnM view 373
17.1.1.4.1 Key strengths 373
17.1.1.4.2 Strategic choices 373
17.1.1.4.3 Weaknesses & competitive threats 374
17.1.2 F. HOFFMANN-LA ROCHE LTD. 375
17.1.2.1 Business overview 375
17.1.2.2 Products offered 376
17.1.2.3 Recent developments 378
17.1.2.3.1 Product launches & approvals 378
17.1.2.3.2 Deals 379
17.1.2.3.3 Expansions 379
17.1.2.4 MnM view 379
17.1.2.4.1 Key strengths 379
17.1.2.4.2 Strategic choices 380
17.1.2.4.3 Weaknesses & competitive threats 380
17.1.3 BIOMÉRIEUX 381
17.1.3.1 Business overview 381
17.1.3.2 Products offered 382
17.1.3.3 Recent developments 384
17.1.3.3.1 Product launches & approvals 384
17.1.3.3.2 Deals 386
17.1.3.4 MnM view 386
17.1.3.4.1 Key strengths 386
17.1.3.4.2 Strategic choices 386
17.1.3.4.3 Weaknesses & competitive threats 386
17.1.4 HOLOGIC, INC. 387
17.1.4.1 Business overview 387
17.1.4.2 Products offered 388
17.1.4.3 Recent developments 389
17.1.4.3.1 Product approvals 389
17.1.4.4 MnM view 390
17.1.4.4.1 Key strengths 390
17.1.4.4.2 Strategic choices 390
17.1.4.4.3 Weaknesses & competitive threats 390
17.1.5 ABBOTT 391
17.1.5.1 Business overview 391
17.1.5.2 Products offered 392
17.1.5.3 Recent developments 394
17.1.5.3.1 Product approvals 394
17.1.5.3.2 Deals 394
17.1.5.4 MnM view 394
17.1.5.4.1 Key strengths 394
17.1.5.4.2 Strategic choices 394
17.1.5.4.3 Weaknesses & competitive threats 395
17.1.6 THERMO FISHER SCIENTIFIC INC. 396
17.1.6.1 Business overview 396
17.1.6.2 Products offered 397
17.1.6.3 Recent developments 398
17.1.6.3.1 Product launches 398
17.1.6.3.2 Deals 399
17.1.7 QIAGEN 400
17.1.7.1 Business overview 400
17.1.7.2 Products offered 401
17.1.7.3 Recent developments 402
17.1.7.3.1 Product launches & approvals 402
17.1.7.3.2 Deals 404
17.1.7.3.3 Expansions 404
17.1.8 REVVITY 405
17.1.8.1 Business overview 405
17.1.8.2 Products offered 407
17.1.9 GRIFOLS, S.A. 408
17.1.9.1 Business overview 408
17.1.9.2 Products offered 410
17.1.9.3 Recent developments 410
17.1.9.3.1 Product approvals 410
17.1.10 SEEGENE INC. 411
17.1.10.1 Business overview 411
17.1.10.2 Products offered 412
17.1.10.3 Recent developments 413
17.1.10.3.1 Product approvals 413
17.1.10.3.2 Deals 414
17.1.11 DIASORIN S.P.A. 415
17.1.11.1 Business overview 415
17.1.11.2 Products offered 416
17.1.11.3 Recent developments 418
17.1.11.3.1 Product approvals 418
17.1.11.3.2 Deals 419
17.1.12 SIEMENS HEALTHINEERS AG 420
17.1.12.1 Business overview 420
17.1.12.2 Products offered 421
17.1.12.3 Recent developments 422
17.1.12.3.1 Deals 422
17.1.12.3.2 Expansions 423
17.1.13 BECTON, DICKINSON AND COMPANY (BD) 424
17.1.13.1 Business overview 424
17.1.13.2 Products offered 425
17.1.13.3 Recent developments 426
17.1.13.3.1 Product approvals 426
17.1.13.3.2 Deals 427
17.1.13.3.3 Expansions 427
17.1.14 SD BIOSENSOR 428
17.1.14.1 Business overview 428
17.1.14.2 Products offered 429
17.1.14.3 Recent developments 430
17.1.14.3.1 Deals 430
17.2 OTHER PLAYERS 431
17.2.1 QUIDELORTHO CORPORATION 431
17.2.2 BRUKER 433
17.2.3 GENETIC SIGNATURES 435
17.2.4 CO-DIAGNOSTICS, INC. 436
17.2.5 VELA DIAGNOSTICS 437
17.2.6 MOLBIO DIAGNOSTICS PVT. LTD. 438
17.2.7 SAVYON DIAGNOSTICS 440
17.2.8 UNIOGEN OY 441
17.2.9 GENEOMBIO TECHNOLOGIES 442
17.2.10 ADVANCED MOLECULAR DIAGNOSTICS 443
17.2.11 ALTONA DIAGNOSTICS GMBH 445
17.2.12 GENEFIRST LIMITED 446
18 RESEARCH METHODOLOGY 447
18.1 RESEARCH DATA 447
18.2 SECONDARY DATA 448
18.2.1 LIST OF SECONDARY SOURCES 448
18.2.2 KEY DATA FROM SECONDARY SOURCES 449
18.2.3 PRIMARY DATA 449
18.2.3.1 List of primary sources 450
18.2.3.2 Key data from primary sources 450
18.2.3.3 Key industry insights 452
18.2.3.4 Breakdown of primary interviews 452
18.3 MARKET SIZE ESTIMATION 453
18.3.1 TOTAL MARKET SIZE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET 453
18.3.2 BOTTOM-UP APPROACH 453
18.3.2.1 Approach 1: Revenue estimation of key players 453
18.3.2.2 Approach 2: Study of annual reports and investor presentations 454
18.3.2.3 Approach 3: Primary interviews 454
18.3.2.4 Growth forecast 454
18.3.2.5 CAGR projections 455
18.3.3 TOP-DOWN APPROACH 455
18.4 DATA TRIANGULATION 456
18.5 RESEARCH ASSUMPTIONS 457
18.5.1 STUDY-RELATED ASSUMPTIONS 457
18.6 STUDY ASSUMPTIONS 457
18.6.1 PARAMETRIC ASSUMPTIONS 458
18.6.2 GROWTH RATE ASSUMPTIONS 458
18.7 RESEARCH LIMITATIONS 459
18.8 RISK ASSESSMENT 459
19 APPENDIX 460
19.1 DISCUSSION GUIDE 460
19.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 465
19.3 RELATED REPORTS 467
19.4 AUTHOR DETAILS 468

LIST OF TABLES

TABLE 1 ESTIMATED NUMBER OF PEOPLE LIVING WITH HIV, ALL AGES, 2010 VS. 2023 VS. 2024 (MILLION PEOPLE) 56
TABLE 2 TOTAL TB INCIDENCE, 2024 56
TABLE 3 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS 68
TABLE 4 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030 69
TABLE 5 NORTH AMERICA: MACROECONOMIC INDICATORS 71
TABLE 6 EUROPE: MACROECONOMIC INDICATORS 71
TABLE 7 ASIA PACIFIC: MACROECONOMIC INDICATORS 71
TABLE 8 LATIN AMERICA: MACROECONOMIC INDICATORS 72
TABLE 9 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 72
TABLE 10 AVERAGE SELLING PRICE TREND OF MOLECULAR INFECTIOUS DISEASE TESTING PRODUCTS, BY KEY PLAYER, 2024–2026 (USD) 77
TABLE 11 AVERAGE SELLING PRICE TREND OF MOLECULAR INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2024–2026 (USD) 77
TABLE 12 IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 78
TABLE 13 EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 79
TABLE 14 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: KEY CONFERENCES & EVENTS, 2026–2027 80
TABLE 15 US-ADJUSTED RECIPROCAL TARIFF RATES 82
TABLE 16 KEY PATENTS IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET, 2022–2026 91
TABLE 17 KEY COMPANIES IMPLEMENTING AI IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET 95
TABLE 18 CLASSIFICATION OF IVD DEVICES IN EUROPE 97
TABLE 19 TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN 99
TABLE 20 CLASSIFICATION OF IVD MEDICAL DEVICES IN AUSTRALIA 100
TABLE 21 NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 102
TABLE 22 EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 102
TABLE 23 ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 102
TABLE 24 LATIN AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103
TABLE 25 REST OF THE WORLD: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103
TABLE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE (%) 107
TABLE 27 KEY BUYING CRITERIA, BY PRODUCT & SERVICE 107
TABLE 28 ADOPTION BARRIERS & INTERNAL CHALLENGES 108
TABLE 29 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 109
TABLE 30 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 113
TABLE 31 KEY REAGENTS & KITS AVAILABLE IN MARKET 114
TABLE 32 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR REAGENTS & KITS, BY REGION, 2024–2031 (USD MILLION) 115
TABLE 33 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR REAGENTS & KITS, BY COUNTRY, 2024–2031 (USD MILLION) 115
TABLE 34 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR REAGENTS & KITS, BY COUNTRY, 2024–2031 (USD MILLION) 116
TABLE 35 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR REAGENTS & KITS, BY COUNTRY, 2024–2031 (USD MILLION) 116
TABLE 36 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR REAGENTS & KITS, BY COUNTRY, 2024–2031 (USD MILLION) 117
TABLE 37 KEY INSTRUMENTS AVAILABLE IN MARKET 118
TABLE 38 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INSTRUMENTS, BY REGION, 2024–2031 (USD MILLION) 119
TABLE 39 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 119
TABLE 40 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 120
TABLE 41 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 120
TABLE 42 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 121
TABLE 43 KEY SOFTWARE & SERVICES AVAILABLE IN MARKET 122
TABLE 44 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SOFTWARE & SERVICES, BY REGION, 2024–2031 (USD MILLION) 122
TABLE 45 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 123
TABLE 46 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 123
TABLE 47 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 123
TABLE 48 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 124
TABLE 49 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 126
TABLE 50 KEY MULTIPLEX TESTING PRODUCTS AVAILABLE IN MARKET 127
TABLE 51 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MULTIPLEX TESTING, BY REGION, 2024–2031 (USD MILLION) 128
TABLE 52 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MULTIPLEX TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 128
TABLE 53 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MULTIPLEX TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 129
TABLE 54 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MULTIPLEX TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 129
TABLE 55 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MULTIPLEX TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 129
TABLE 56 KEY SINGLEPLEX TESTING PRODUCTS AVAILABLE IN MARKET 130
TABLE 57 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SINGLEPLEX TESTING, BY REGION, 2024–2031 (USD MILLION) 131
TABLE 58 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SINGLEPLEX TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 131
TABLE 59 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SINGLEPLEX TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 132
TABLE 60 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SINGLEPLEX TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 132
TABLE 61 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SINGLEPLEX TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 132
TABLE 62 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 134
TABLE 63 KEY LABORATORY-BASED TESTS AVAILABLE IN MARKET 135
TABLE 64 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR LABORATORY TESTS, BY REGION, 2024–2031 (USD MILLION) 136
TABLE 65 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR LABORATORY TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 136
TABLE 66 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR LABORATORY TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 137
TABLE 67 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR LABORATORY TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 137
TABLE 68 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR LABORATORY TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 138
TABLE 69 KEY POINT-OF-CARE TESTS AVAILABLE IN MARKET 139
TABLE 70 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POINT-OF-CARE TESTS, BY REGION, 2024–2031 (USD MILLION) 140
TABLE 71 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 140
TABLE 72 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 141
TABLE 73 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 141
TABLE 74 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 142
TABLE 75 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 144
TABLE 76 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 145
TABLE 77 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION) 146
TABLE 78 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 146
TABLE 79 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 147
TABLE 80 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 147
TABLE 81 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 148
TABLE 82 KEY INFLUENZA TESTING PRODUCTS AVAILABLE IN MARKET 149
TABLE 83 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INFLUENZA, BY REGION, 2024–2031 (USD MILLION) 149
TABLE 84 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INFLUENZA, BY COUNTRY, 2024–2031 (USD MILLION) 150
TABLE 85 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INFLUENZA, BY COUNTRY, 2024–2031 (USD MILLION) 150
TABLE 86 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INFLUENZA, BY COUNTRY, 2024–2031 (USD MILLION) 150
TABLE 87 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INFLUENZA, BY COUNTRY, 2024–2031 (USD MILLION) 151
TABLE 88 KEY TUBERCULOSIS TESTING PRODUCTS AVAILABLE IN MARKET 152
TABLE 89 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR TUBERCULOSIS, BY REGION, 2024–2031 (USD MILLION) 152
TABLE 90 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR TUBERCULOSIS, BY COUNTRY, 2024–2031 (USD MILLION) 152
TABLE 91 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR TUBERCULOSIS, BY COUNTRY, 2024–2031 (USD MILLION) 153
TABLE 92 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR TUBERCULOSIS, BY COUNTRY, 2024–2031 (USD MILLION) 153
TABLE 93 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR TUBERCULOSIS, BY COUNTRY, 2024–2031 (USD MILLION) 153
TABLE 94 KEY PHARYNGITIS TESTING PRODUCTS AVAILABLE IN MARKET 154
TABLE 95 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR PHARYNGITIS, BY REGION, 2024–2031 (USD MILLION) 155
TABLE 96 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR PHARYNGITIS, BY COUNTRY, 2024–2031 (USD MILLION) 155
TABLE 97 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR PHARYNGITIS, BY COUNTRY, 2024–2031 (USD MILLION) 155
TABLE 98 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR PHARYNGITIS, BY COUNTRY, 2024–2031 (USD MILLION) 156
TABLE 99 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR PHARYNGITIS, BY COUNTRY, 2024–2031 (USD MILLION) 156
TABLE 100 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NON-TUBERCULOUS MYCOBACTERIA (NTM) LUNG INFECTIONS, BY REGION, 2024–2031 (USD MILLION) 157
TABLE 101 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NON-TUBERCULOUS MYCOBACTERIA (NTM) LUNG INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION) 158
TABLE 102 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NON-TUBERCULOUS MYCOBACTERIA (NTM) LUNG INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION) 158
TABLE 103 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NON-TUBERCULOUS MYCOBACTERIA (NTM) LUNG INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION) 159
TABLE 104 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NON-TUBERCULOUS MYCOBACTERIA (NTM) LUNG INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION) 159
TABLE 105 OTHER KEY RESPIRATORY INFECTION DISEASE TESTING PRODUCTS AVAILABLE IN MARKET 160
TABLE 106 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION) 161
TABLE 107 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 161
TABLE 108 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 161
TABLE 109 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 162
TABLE 110 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 162
TABLE 111 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 163
TABLE 112 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION) 163
TABLE 113 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 163
TABLE 114 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 164
TABLE 115 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 164
TABLE 116 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 164
TABLE 117 KEY HEPATITIS TESTING PRODUCTS AVAILABLE IN MARKET 166
TABLE 118 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HEPATITIS, BY REGION, 2024–2031 (USD MILLION) 166
TABLE 119 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HEPATITIS, BY COUNTRY, 2024–2031 (USD MILLION) 167
TABLE 120 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HEPATITIS, BY COUNTRY, 2024–2031 (USD MILLION) 167
TABLE 121 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HEPATITIS, BY COUNTRY, 2024–2031 (USD MILLION) 167
TABLE 122 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HEPATITIS, BY COUNTRY, 2024–2031 (USD MILLION) 168
TABLE 123 OTHER KEY GASTROINTESTINAL INFECTIOUS DISEASE TESTING PRODUCTS AVAILABLE IN MARKET 169
TABLE 124 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER GASTROINTESTINAL INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION) 169
TABLE 125 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 169
TABLE 126 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 170
TABLE 127 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 170
TABLE 128 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 170
TABLE 129 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 171
TABLE 130 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY REGION, 2024–2031 (USD MILLION) 172
TABLE 131 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 172
TABLE 132 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 173
TABLE 133 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 173
TABLE 134 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 173
TABLE 135 KEY HIV TESTING PRODUCTS AVAILABLE IN MARKET 175
TABLE 136 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HIV, BY REGION, 2024–2031 (USD MILLION) 175
TABLE 137 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HIV, BY COUNTRY, 2024–2031 (USD MILLION) 176
TABLE 138 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HIV, BY COUNTRY, 2024–2031 (USD MILLION) 176
TABLE 139 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HIV, BY COUNTRY, 2024–2031 (USD MILLION) 176
TABLE 140 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HIV, BY COUNTRY, 2024–2031 (USD MILLION) 177
TABLE 141 KEY HUMAN PAPILLOMAVIRUS TESTING PRODUCTS AVAILABLE IN MARKET 178
TABLE 142 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HUMAN PAPILLOMAVIRUS, BY REGION, 2024–2031 (USD MILLION) 178
TABLE 143 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HUMAN PAPILLOMAVIRUS, BY COUNTRY, 2024–2031 (USD MILLION) 179
TABLE 144 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HUMAN PAPILLOMAVIRUS, BY COUNTRY, 2024–2031 (USD MILLION) 179
TABLE 145 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HUMAN PAPILLOMAVIRUS, BY COUNTRY, 2024–2031 (USD MILLION) 179
TABLE 146 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HUMAN PAPILLOMAVIRUS, BY COUNTRY, 2024–2031 (USD MILLION) 180
TABLE 147 KEY CHLAMYDIA TRACHOMATIS TESTING PRODUCTS AVAILABLE IN MARKET 180
TABLE 148 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR CHLAMYDIA TRACHOMATIS, BY REGION, 2024–2031 (USD MILLION) 181
TABLE 149 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2024–2031 (USD MILLION) 181
TABLE 150 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2024–2031 (USD MILLION) 182
TABLE 151 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2024–2031 (USD MILLION) 182
TABLE 152 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2024–2031 (USD MILLION) 183
TABLE 153 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NEISSERIA GONORRHOEAE, BY REGION, 2024–2031 (USD MILLION) 184
TABLE 154 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NEISSERIA GONORRHOEA, BY COUNTRY, 2024–2031 (USD MILLION) 184
TABLE 155 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2024–2031 (USD MILLION) 185
TABLE 156 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2024–2031 (USD MILLION) 185
TABLE 157 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2024–2031 (USD MILLION) 185
TABLE 158 KEY SYPHILIS TESTING PRODUCTS AVAILABLE IN MARKET 186
TABLE 159 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SYPHILIS, BY REGION, 2024–2031 (USD MILLION) 187
TABLE 160 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SYPHILIS, BY COUNTRY, 2024–2031 (USD MILLION) 187
TABLE 161 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SYPHILIS, BY COUNTRY, 2024–2031 (USD MILLION) 188
TABLE 162 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SYPHILIS, BY COUNTRY, 2024–2031 (USD MILLION) 188
TABLE 163 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SYPHILIS, BY COUNTRY, 2024–2031 (USD MILLION) 189
TABLE 164 OTHER KEY SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS AVAILABLE IN MARKET 190
TABLE 165 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY REGION, 2024–2031 (USD MILLION) 190
TABLE 166 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 191
TABLE 167 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 191
TABLE 168 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 191
TABLE 169 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 192
TABLE 170 KEY HOSPITAL-ACQUIRED INFECTION TESTING PRODUCTS AVAILABLE IN MARKET 193
TABLE 171 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2024–2031 (USD MILLION) 193
TABLE 172 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION) 193
TABLE 173 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION) 194
TABLE 174 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION) 194
TABLE 175 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION) 194
TABLE 176 KEY VAGINITIS TESTING PRODUCTS AVAILABLE IN MARKET 195
TABLE 177 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VAGINITIS, BY REGION, 2024–2031 (USD MILLION) 196
TABLE 178 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VAGINITIS, BY COUNTRY, 2024–2031 (USD MILLION) 196
TABLE 179 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VAGINITIS, BY COUNTRY, 2024–2031 (USD MILLION) 197
TABLE 180 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VAGINITIS, BY COUNTRY, 2024–2031 (USD MILLION) 197
TABLE 181 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VAGINITIS, BY COUNTRY, 2024–2031 (USD MILLION) 198
TABLE 182 KEY MENINGITIS TESTING PRODUCTS AVAILABLE IN MARKET 199
TABLE 183 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MENINGITIS, BY REGION, 2024–2031 (USD MILLION) 199
TABLE 184 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MENINGITIS, BY COUNTRY, 2024–2031 (USD MILLION) 199
TABLE 185 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MENINGITIS, BY COUNTRY, 2024–2031 (USD MILLION) 200
TABLE 186 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MENINGITIS, BY COUNTRY, 2024–2031 (USD MILLION) 200
TABLE 187 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MENINGITIS, BY COUNTRY, 2024–2031 (USD MILLION) 201
TABLE 188 KEY VECTOR-BORNE DISEASE TESTING PRODUCTS AVAILABLE IN MARKET 202
TABLE 189 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VECTOR-BORNE DISEASES, BY REGION, 2024–2031 (USD MILLION) 203
TABLE 190 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VECTOR-BORNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 203
TABLE 191 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VECTOR-BORNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 204
TABLE 192 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VECTOR-BORNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 204
TABLE 193 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VECTOR-BORNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 204
TABLE 194 KEY BLOODSTREAM INFECTIONS & SEPSIS TESTING PRODUCTS AVAILABLE IN MARKET 205
TABLE 195 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR BLOODSTREAM INFECTIONS & SEPSIS, BY REGION, 2024–2031 (USD MILLION) 206
TABLE 196 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR BLOODSTREAM INFECTIONS & SEPSIS, BY COUNTRY, 2024–2031 (USD MILLION) 206
TABLE 197 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR BLOODSTREAM INFECTIONS & SEPSIS, BY COUNTRY, 2024–2031 (USD MILLION) 207
TABLE 198 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR BLOODSTREAM INFECTIONS & SEPSIS, BY COUNTRY, 2024–2031 (USD MILLION) 207
TABLE 199 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR BLOODSTREAM INFECTIONS & SEPSIS, BY COUNTRY, 2024–2031 (USD MILLION) 207
TABLE 200 OTHER KEY INFECTIOUS DISEASE TESTING PRODUCTS AVAILABLE IN MARKET 208
TABLE 201 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION) 209
TABLE 202 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 209
TABLE 203 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 210
TABLE 204 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 210
TABLE 205 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 210
TABLE 206 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 212
TABLE 207 KEY POLYMERASE CHAIN REACTION-BASED TESTS AND DEVICES AVAILABLE IN MARKET 214
TABLE 208 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2024–2031 (USD MILLION) 215
TABLE 209 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2024–2031 (USD MILLION) 215
TABLE 210 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2024–2031 (USD MILLION) 216
TABLE 211 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2024–2031 (USD MILLION) 216
TABLE 212 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2024–2031 (USD MILLION) 217
TABLE 213 KEY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY-BASED TESTS AND DEVICES AVAILABLE IN MARKET 218
TABLE 214 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2024–2031 (USD MILLION) 218
TABLE 215 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 219
TABLE 216 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 219
TABLE 217 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 219
TABLE 218 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 220
TABLE 219 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2024–2031 (USD MILLION) 221
TABLE 220 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION) 221
TABLE 221 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION) 222
TABLE 222 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION) 222
TABLE 223 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION) 223
TABLE 224 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2024–2031 (USD MILLION) 224
TABLE 225 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2024–2031 (USD MILLION) 224
TABLE 226 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2024–2031 (USD MILLION) 225
TABLE 227 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2024–2031 (USD MILLION) 225
TABLE 228 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2024–2031 (USD MILLION) 226
TABLE 229 KEY MICROARRAY-BASED PRODUCTS AVAILABLE IN MARKET 226
TABLE 230 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA MICROARRAYS, BY REGION, 2024–2031 (USD MILLION) 227
TABLE 231 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2024–2031 (USD MILLION) 227
TABLE 232 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2024–2031 (USD MILLION) 227
TABLE 233 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2024–2031 (USD MILLION) 228
TABLE 234 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2024–2031 (USD MILLION) 228
TABLE 235 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2024–2031 (USD MILLION) 229
TABLE 236 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 229
TABLE 237 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 230
TABLE 238 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 230
TABLE 239 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 230
TABLE 240 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 232
TABLE 241 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 233
TABLE 242 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 234
TABLE 243 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 234
TABLE 244 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 234
TABLE 245 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 235
TABLE 246 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITALS & CLINICS, BY REGION, 2024–2031 (USD MILLION) 236
TABLE 247 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 236
TABLE 248 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 237
TABLE 249 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 237
TABLE 250 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 237
TABLE 251 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION) 238
TABLE 252 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 238
TABLE 253 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 239
TABLE 254 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 239
TABLE 255 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 239
TABLE 256 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY REGION, 2024–2031 (USD MILLION) 241
TABLE 257 NORTH AMERICA: MACROECONOMIC INDICATORS 243
TABLE 258 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 244
TABLE 259 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 244
TABLE 260 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 244
TABLE 261 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 245
TABLE 262 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 245
TABLE 263 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 246
TABLE 264 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 246
TABLE 265 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 247
TABLE 266 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 247
TABLE 267 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 248
TABLE 268 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 249
TABLE 269 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 249
TABLE 270 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 249
TABLE 271 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 250
TABLE 272 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 250
TABLE 273 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 251
TABLE 274 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 251
TABLE 275 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 252
TABLE 276 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 252
TABLE 277 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 253
TABLE 278 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 253
TABLE 279 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 254
TABLE 280 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 254
TABLE 281 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 255
TABLE 282 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 255
TABLE 283 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 256
TABLE 284 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 256
TABLE 285 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 257
TABLE 286 MACROECONOMIC INDICATORS FOR EUROPE 258
TABLE 287 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 258
TABLE 288 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 258
TABLE 289 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 259
TABLE 290 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 259
TABLE 291 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 259
TABLE 292 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 260
TABLE 293 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 260
TABLE 294 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 261
TABLE 295 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 261
TABLE 296 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 262
TABLE 297 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 263
TABLE 298 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 263
TABLE 299 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 263
TABLE 300 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 264
TABLE 301 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 264
TABLE 302 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 265
TABLE 303 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 265
TABLE 304 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 266
TABLE 305 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 266
TABLE 306 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 267
TABLE 307 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 268
TABLE 308 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 268
TABLE 309 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 268
TABLE 310 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 269
TABLE 311 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 269
TABLE 312 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 270
TABLE 313 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 270
TABLE 314 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 271
TABLE 315 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 272
TABLE 316 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 272
TABLE 317 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 272
TABLE 318 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 273
TABLE 319 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 273
TABLE 320 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 274
TABLE 321 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 274
TABLE 322 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 275
TABLE 323 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 275
TABLE 324 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 276
TABLE 325 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 276
TABLE 326 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 277
TABLE 327 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 277
TABLE 328 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 278
TABLE 329 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 278
TABLE 330 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 279
TABLE 331 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 279
TABLE 332 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 280
TABLE 333 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 281
TABLE 334 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 281
TABLE 335 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 281
TABLE 336 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 282
TABLE 337 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 282
TABLE 338 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 283
TABLE 339 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 283
TABLE 340 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 284
TABLE 341 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 284
TABLE 342 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 285
TABLE 343 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 285
TABLE 344 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 286
TABLE 345 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 286
TABLE 346 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 287
TABLE 347 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 287
TABLE 348 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 288
TABLE 349 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 288
TABLE 350 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 289
TABLE 351 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 290
TABLE 352 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 290
TABLE 353 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 290
TABLE 354 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 291
TABLE 355 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 291
TABLE 356 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 292
TABLE 357 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 292
TABLE 358 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 293
TABLE 359 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 293
TABLE 360 MACROECONOMIC INDICATORS FOR ASIA PACIFIC 295
TABLE 361 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 296
TABLE 362 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 296
TABLE 363 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 296
TABLE 364 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 297
TABLE 365 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 297
TABLE 366 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 298
TABLE 367 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 298
TABLE 368 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 299
TABLE 369 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 299
TABLE 370 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 300
TABLE 371 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 301
TABLE 372 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 301
TABLE 373 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 301
TABLE 374 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 302
TABLE 375 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 302
TABLE 376 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 303
TABLE 377 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 303
TABLE 378 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 304
TABLE 379 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 304
TABLE 380 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 305
TABLE 381 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 306
TABLE 382 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 306
TABLE 383 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 306
TABLE 384 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 307
TABLE 385 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 307
TABLE 386 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 308
TABLE 387 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 308
TABLE 388 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 309
TABLE 389 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 310
TABLE 390 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 310
TABLE 391 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 310
TABLE 392 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 311
TABLE 393 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 311
TABLE 394 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 312
TABLE 395 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 312
TABLE 396 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 313
TABLE 397 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 313
TABLE 398 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 314
TABLE 399 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 315
TABLE 400 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 315
TABLE 401 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 315
TABLE 402 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 316
TABLE 403 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 316
TABLE 404 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 317
TABLE 405 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 317
TABLE 406 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 318
TABLE 407 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 319
TABLE 408 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 319
TABLE 409 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 319
TABLE 410 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 320
TABLE 411 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 320
TABLE 412 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 321
TABLE 413 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 321
TABLE 414 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 322
TABLE 415 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 322
TABLE 416 MACROECONOMIC INDICATORS FOR LATIN AMERICA 323
TABLE 417 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 324
TABLE 418 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 324
TABLE 419 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 324
TABLE 420 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 325
TABLE 421 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 325
TABLE 422 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 326
TABLE 423 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 326
TABLE 424 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 327
TABLE 425 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 327
TABLE 426 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 328
TABLE 427 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 329
TABLE 428 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 329
TABLE 429 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 329
TABLE 430 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 330
TABLE 431 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 330
TABLE 432 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 331
TABLE 433 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 331
TABLE 434 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 332
TABLE 435 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 332
TABLE 436 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 333
TABLE 437 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 333
TABLE 438 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 334
TABLE 439 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 334
TABLE 440 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 335
TABLE 441 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 335
TABLE 442 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 336
TABLE 443 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 336
TABLE 444 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 337
TABLE 445 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 338
TABLE 446 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 338
TABLE 447 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 338
TABLE 448 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 339
TABLE 449 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 339
TABLE 450 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 340
TABLE 451 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 340
TABLE 452 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 341
TABLE 453 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 341
TABLE 454 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 342
TABLE 455 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 343
TABLE 456 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 343
TABLE 457 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 343
TABLE 458 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 344
TABLE 459 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 344
TABLE 460 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 345
TABLE 461 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 345
TABLE 462 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 346
TABLE 463 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 347
TABLE 464 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 347
TABLE 465 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 347
TABLE 466 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 348
TABLE 467 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 348
TABLE 468 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 349
TABLE 469 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 349
TABLE 470 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 350
TABLE 471 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 350
TABLE 472 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET, JANUARY 2023−APRIL 2026 351
TABLE 473 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: DEGREE OF COMPETITION 354
TABLE 474 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: REGION FOOTPRINT 358
TABLE 475 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: PRODUCT & SERVICE FOOTPRINT 359
TABLE 476 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: DISEASE FOOTPRINT 360
TABLE 477 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: TEST TYPE FOOTPRINT 361
TABLE 478 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: DETAILED LIST OF KEY STARTUPS/SMES 363
TABLE 479 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2) 363
TABLE 480 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2) 364
TABLE 481 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026 366
TABLE 482 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: DEALS, JANUARY 2023–APRIL 2026 367
TABLE 483 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: EXPANSIONS, JANUARY 2023–APRIL 2026 368
TABLE 484 DANAHER: COMPANY OVERVIEW 369
TABLE 485 DANAHER: PRODUCTS OFFERED 370
TABLE 486 DANAHER: PRODUCT APPROVALS, JANUARY 2023–APRIL 2026 372
TABLE 487 DANAHER: DEALS, JANUARY 2023–APRIL 2026 373
TABLE 488 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 375
TABLE 489 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 376
TABLE 490 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026 378
TABLE 491 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2023–APRIL 2026 379
TABLE 492 F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2023–APRIL 2026 379
TABLE 493 BIOMÉRIEUX: COMPANY OVERVIEW 381
TABLE 494 BIOMÉRIEUX: PRODUCTS OFFERED 382
TABLE 495 BIOMÉRIEUX: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026 384
TABLE 496 BIOMÉRIEUX: DEALS, JANUARY 2023–APRIL 2026 386
TABLE 497 HOLOGIC, INC.: COMPANY OVERVIEW 387
TABLE 498 HOLOGIC, INC.: PRODUCTS OFFERED 388
TABLE 499 HOLOGIC, INC.: PRODUCT APPROVALS, JANUARY 2023–APRIL 2026 389
TABLE 500 ABBOTT: COMPANY OVERVIEW 391
TABLE 501 ABBOTT: PRODUCTS OFFERED 392
TABLE 502 ABBOTT: PRODUCT APPROVALS, JANUARY 2023–APRIL 2026 394
TABLE 503 ABBOTT: DEALS, JANUARY 2023–APRIL 2026 394
TABLE 504 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 396
TABLE 505 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 397
TABLE 506 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES, JANUARY 2023–APRIL 2026 398
TABLE 507 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2023–APRIL 2026 399
TABLE 508 QIAGEN: COMPANY OVERVIEW 400
TABLE 509 QIAGEN : PRODUCTS OFFERED 401
TABLE 510 QIAGEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–DECEMBER 2024 402
TABLE 511 QIAGEN: DEALS, JANUARY 2021–DECEMBER 2024 404
TABLE 512 QIAGEN: EXPANSIONS, JANUARY 2021–DECEMBER 2024 404
TABLE 513 REVVITY: COMPANY OVERVIEW 405
TABLE 514 REVVITY: PRODUCTS OFFERED 407
TABLE 515 GRIFOLS, S.A.: COMPANY OVERVIEW 408
TABLE 516 GRIFOLS, S.A.: PRODUCTS OFFERED 410
TABLE 517 GRIFOLS, S.A.: PRODUCT APPROVALS, JANUARY 2023–APRIL 2026 410
TABLE 518 SEEGENE INC.: COMPANY OVERVIEW 411
TABLE 519 SEEGENE INC.: PRODUCTS OFFERED 412
TABLE 520 SEEGENE INC.: PRODUCT APPROVALS, JANUARY 2023–APRIL 2026 413
TABLE 521 SEEGENE INC.: DEALS, JANUARY 2023–APRIL 2026 414
TABLE 522 DIASORIN S.P.A.: COMPANY OVERVIEW 415
TABLE 523 DIASORIN S.P.A.: PRODUCTS OFFERED 416
TABLE 524 DIASORIN S.P.A.: PRODUCT APPROVALS, JANUARY 2023–APRIL 2026 418
TABLE 525 DIASORIN S.P.A.: DEALS, JANUARY 2023–APRIL 2026 419
TABLE 526 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 420
TABLE 527 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED 421
TABLE 528 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2023–APRIL 2026 422
TABLE 529 SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2023–APRIL 2026 423
TABLE 530 BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW 424
TABLE 531 BECTON, DICKINSON AND COMPANY (BD): PRODUCTS OFFERED 425
TABLE 532 BD: PRODUCT APPROVALS, JANUARY 2023–APRIL 2026 426
TABLE 533 BD: DEALS, JANUARY 2023–APRIL 2026 427
TABLE 534 BD: EXPANSIONS, JANUARY 2023–APRIL 2026 427
TABLE 535 SD BIOSENSOR: COMPANY OVERVIEW 428
TABLE 536 SD BIOSENSOR: PRODUCTS OFFERED 429
TABLE 537 SD BIOSENSOR: DEALS, JANUARY 2023–APRIL 2026 430
TABLE 538 QUIDELORTHO CORPORATION: COMPANY OVERVIEW 431
TABLE 539 BRUKER: COMPANY OVERVIEW 433
TABLE 540 GENETIC SIGNATURES: COMPANY OVERVIEW 435
TABLE 541 CO-DIAGNOSTICS, INC.: COMPANY OVERVIEW 436
TABLE 542 VELA DIAGNOSTICS: COMPANY OVERVIEW 437
TABLE 543 MOLBIO DIAGNOSTICS PVT. LTD.: COMPANY OVERVIEW 438
TABLE 544 SAVYON DIAGNOSTICS: COMPANY OVERVIEW 440
TABLE 545 UNIOGEN OY: COMPANY OVERVIEW 441
TABLE 546 GENEOMBIO TECHNOLOGIES: COMPANY OVERVIEW 442
TABLE 547 ADVANCED MOLECULAR DIAGNOSTICS: COMPANY OVERVIEW 443
TABLE 548 ALTONA DIAGNOSTICS GMBH: COMPANY OVERVIEW 445
TABLE 549 GENEFIRST LIMITED: COMPANY OVERVIEW 446
TABLE 550 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: RISK ASSESSMENT 459

LIST OF FIGURES

FIGURE 1 MOLECULAR INFECTIOUS DISEASE TESTING MARKET SEGMENTATION & REGIONAL SCOPE 41
FIGURE 2 KEY INSIGHTS & MARKET HIGHLIGHTS 45
FIGURE 3 GLOBAL MOLECULAR INFECTIOUS DISEASE TESTING MARKET, 2024–2031 45
FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET, 2023–2025 46
FIGURE 5 DISRUPTIVE TRENDS IMPACTING GROWTH OF MOLECULAR INFECTIOUS DISEASE TESTING MARKET 47
FIGURE 6 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET, 2025 48
FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 49
FIGURE 8 RISING CASES OF INFECTIOUS DISEASES TO DRIVE MARKET 50
FIGURE 9 REAGENTS & KITS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 50
FIGURE 10 MULTIPLEX TESTING SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 51
FIGURE 11 LABORATORY TESTS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 51
FIGURE 12 STDS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 52
FIGURE 13 POLYMERASE CHAIN REACTION SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 52
FIGURE 14 DIAGNOSTIC LABORATORIES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 53
FIGURE 15 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 53
FIGURE 16 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 54
FIGURE 17 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS 67
FIGURE 18 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: SUPPLY CHAIN ANALYSIS 73
FIGURE 19 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: VALUE CHAIN ANALYSIS 74
FIGURE 20 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: ECOSYSTEM ANALYSIS 75
FIGURE 21 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 81
FIGURE 22 NUMBER OF DEALS & FUNDING ACTIVITIES IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET 82
FIGURE 23 PATENT ANALYSIS FOR MOLECULAR INFECTIOUS DISEASE TESTING MARKET, JANUARY 2016–DECEMBER 2025 91
FIGURE 24 MARKET POTENTIAL OF AI IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET 94
FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE 106
FIGURE 26 KEY BUYING CRITERIA, BY PRODUCT & SERVICE 107
FIGURE 27 REGIONAL INCIDENCE OF HIV, 2023 174
FIGURE 28 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET SNAPSHOT 243
FIGURE 29 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET SNAPSHOT 295
FIGURE 30 REVENUE ANALYSIS OF KEY PLAYERS IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET, 2023–2025 (USD MILLION) 353
FIGURE 31 MOLECULAR INFECTIOUS DISEASE TESTING MARKET SHARE ANALYSIS, 2025 (GLOBAL) 354
FIGURE 32 MOLECULAR INFECTIOUS DISEASE TESTING MARKET SHARE ANALYSIS, 2025 (US) 356
FIGURE 33 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 357
FIGURE 34 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: COMPANY FOOTPRINT 358
FIGURE 35 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 362
FIGURE 36 EV/EBITDA OF KEY VENDORS 364
FIGURE 37 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 365
FIGURE 38 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: BRAND/PRODUCT COMPARISON FOR MOLECULAR INFECTIOUS DISEASE TESTING 365
FIGURE 39 DANAHER: COMPANY SNAPSHOT (2025) 370
FIGURE 40 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2025) 376
FIGURE 41 BIOMÉRIEUX: COMPANY SNAPSHOT (2025) 382
FIGURE 42 HOLOGIC, INC.: COMPANY SNAPSHOT (2024) 388
FIGURE 43 ABBOTT: COMPANY SNAPSHOT (2025) 392
FIGURE 44 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025) 397
FIGURE 45 QIAGEN : COMPANY SNAPSHOT (2024) 401
FIGURE 46 REVVITY: COMPANY SNAPSHOT (2025) 406
FIGURE 47 GRIFOLS, S.A.: COMPANY SNAPSHOT (2025) 409
FIGURE 48 SEEGENE INC.: COMPANY SNAPSHOT (2025) 412
FIGURE 49 DIASORIN S.P.A.: COMPANY SNAPSHOT (2025) 416
FIGURE 50 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2025) 421
FIGURE 51 BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT (2025) 425
FIGURE 52 SD BIOSENSOR: COMPANY SNAPSHOT (2024) 429
FIGURE 53 RESEARCH DESIGN 447
FIGURE 54 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 452
FIGURE 55 TOP-DOWN APPROACH 455
FIGURE 56 DATA TRIANGULATION 456

---

---